Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

NCT04440917 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib Mesylate

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University